News - NAVERIS

Natick company develops test to detect head and neck cancer that could lead to earlier diagnosis

August 4, 2021

“A saliva-based diagnostic test that can detect HPV-related head and neck cancer has the potential to catch the disease earlier and even serve as a standard screening method, which the medical community currently lacks. Oropharyngeal squamous cell carcinoma, a cancer caused by human papillomavirus that develops in the mouth and throat, is expected to cause more than 10,000 deaths this year, according to the American Cancer Society. Cases have been increasing significantly in men in recent years.” Read the full…

New Saliva Test Detects Head and Neck Cancer

June 24, 2021

NAVERIS

Uncategorized

For Release: June 2, 2021 Waltham, MA— A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. Researchers at Washington University School of Medicine in St. Louis used the Naveris, Inc. test to analyze saliva for sequences of the human papilloma virus (HPV) genome that are specific for HPV DNA released from malignant tumors. The test successfully distinguishes this tumor-tissue modified virus from non-cancerous sources of HPV DNA…

Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers

December 15, 2020

NAVERIS

Uncategorized

“NATICK, Mass.–(BUSINESS WIRE)–Naveris, a healthcare company dedicated to improving patient care through early detection of virus-related cancers, today announced the close of its expanded Series A financing, bringing the total raised to over $19 million since the company’s inception. Gurnet Point Capital (GPC), a private investment fund focused in the healthcare and life sciences sector, led the financing round.” Read the full article at BusinessWire.

HPV Head and Neck Cancer Recurrence Test Data Adds Validation as Naveris Ramps Clinical Launch

March 26, 2020

NAVERIS

GenomeWeb

HPV Head and Neck Cancer Recurrence Test Data Adds Validation as Naveris Ramps Clinical Launch Mar 24, 2020 | Molika Ashford NEW YORK – Investigators from the University of North Carolina at Chapel Hill have reached a new milestone for their virus-associated oropharyngeal cancer detection assay, publishing validation data for the test, while a startup has begun to provide the test to early adopters. Appearing last month in the Journal of Clinical Oncology, the group’s study confirmed that the liquid…

Blood Test Accurately Identifies HPV-related Head and Neck Cancer Recurrence; Prospective Clinical Study Published in Journal of Clinical Oncology

February 5, 2020

NAVERIS

Uncategorized

“WALTHAM, Mass.–(BUSINESS WIRE)–A novel blood test can detect recurrent Human Papilloma Virus (HPV)-related head and neck (oropharyngeal) cancers, according to a study published online in the Journal of Clinical Oncology by researchers at the University of North Carolina School of Medicine. The multi-year, prospective study underscores the test’s potential to allow patients with recurrent disease to begin earlier treatment and spare disease-free patients from repeated invasive testing.” Read the full article on BusinessWire.com.

Study finds blood test accurately tracks HPV-linked head and neck cancer

February 4, 2020

NAVERIS

General

“An experimental blood test accurately detected HPV-linked head and neck cancer recurrence and confirmed when patients remained cancer-free, according to findings from a study led by University of North Carolina Lineberger Comprehensive Cancer Center researchers Read the full article at the UNC Lineberger Comprehensive Cancer Center.

Researchers identify traits linked to better outcomes in HPV-linked head and neck cancer

June 14, 2019

NAVERIS

General

“Newswise — Using a new blood test that’s in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.” Read the full article on Newswise.com.

Biomarker blood test accurately confirms remission in patients with HPV-associated oral cancer

October 28, 2018

NAVERIS

General

“A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).” Read the full article on Astro.org.

HEALIO–Liquid biopsy test confirms remission in HPV-associated oral cancer

October 28, 2018

NAVERIS

Uncategorized

Liquid biopsy test confirms remission in HPV-associated oral cancer October 24, 2018 A novel liquid biopsy test showed compelling specificity and sensitivity in detecting HPV DNA among patients who underwent chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma, according to findings presented at the American Society for Radiation Oncology Annual Meeting. “This blood test has exceptional performance in monitoring patients for cancer recurrence after radiation therapy,” Bhisham Chera, MD, an associate professor of radiation oncology at The University of North Carolina…

DENTISTRY TODAY–Blood Test Confirms Remission in HPV-Associated Oral Cancer Patients

October 28, 2018

NAVERIS

Uncategorized

Blood Test Confirms Remission in HPV-Associated Oral Cancer Patients 25 Oct 2018 Dentistry Today UNC Lineberger’s Bhishamjit S. Chera, MD, and Gaorav Gupta, MD, PhD. A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy, according to researchers at the University of North Carolina (UNC) at Chapel Hill. The liquid biopsy test, which measures fragments…